Ginkgo Bioworks Holdings (DNA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ginkgo Bioworks Holdings stock (DNA) is currently trading at $7.17. Ginkgo Bioworks Holdings PS ratio (Price-to-Sales) is 2.44. Analyst consensus price target for DNA is $8.67. WallStSmart rates DNA as Sell.
- DNA PE ratio analysis and historical PE chart
- DNA PS ratio (Price-to-Sales) history and trend
- DNA intrinsic value — DCF, Graham Number, EPV models
- DNA stock price prediction 2025 2026 2027 2028 2029 2030
- DNA fair value vs current price
- DNA insider transactions and insider buying
- Is DNA undervalued or overvalued?
- Ginkgo Bioworks Holdings financial analysis — revenue, earnings, cash flow
- DNA Piotroski F-Score and Altman Z-Score
- DNA analyst price target and Smart Rating
Ginkgo Bioworks Holdings
📊 No data available
Try selecting a different time range
Smart Analysis
Ginkgo Bioworks Holdings (DNA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Ginkgo Bioworks Holdings (DNA) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
73.10% of shares held by major funds and institutions
Supporting Valuation Data
Ginkgo Bioworks Holdings (DNA) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -23.80%, a shrinking business
Company is losing money with a negative profit margin
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.44x sales
Ginkgo Bioworks Holdings (DNA) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.82) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.44) suggest expensive pricing. Growth concerns include Revenue Growth at -23.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -51.10%, Operating Margin at -209.70%, Profit Margin at -183.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -51.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -23.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DNA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DNA's Price-to-Sales ratio of 2.44x trades at a 33% premium to its historical average of 1.84x (74th percentile). The current valuation is 72% below its historical high of 8.75x set in Oct 2021, and 3970% above its historical low of 0.06x in Jun 2024. Over the past 12 months, the PS ratio has expanded from ~1.3x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ginkgo Bioworks Holdings (DNA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ginkgo Bioworks Holdings is in a turnaround phase, with management focused on restoring profitability. Revenue reached 170M with 24% decline year-over-year. The company is currently unprofitable, posting a -183.8% profit margin.
Key Findings
Spending 29% of revenue (50M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 24% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -183.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.59, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ginkgo Bioworks Holdings.
Bottom Line
Ginkgo Bioworks Holdings is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(12 last 3 months)
| Insider | Type | Shares |
|---|---|---|
COEN, STEVEN P. See remarks | Sell | -708 |
| Insider | Type | Shares |
|---|---|---|
COEN, STEVEN P. See remarks | Sell | -972 |
Data sourced from SEC Form 4 filings
Last updated: 8:21:51 AM
About Ginkgo Bioworks Holdings(DNA)
NYSE
HEALTHCARE
BIOTECHNOLOGY
USA
Ginkgo Bioworks Holdings (DNA) is a pioneering leader in the synthetic biology sector, utilizing advanced genetic engineering technologies to create customized bioengineered organisms for applications in pharmaceuticals, agriculture, and industrial biotech. Its proprietary platform significantly enhances cellular design for manufacturing, streamlining product development and production processes. Dedicated to addressing global challenges such as climate change and food security, Ginkgo is strategically positioned to influence a wide array of industries while driving sustainable innovation. With its commitment to bio-based solutions, the company is poised for robust growth in a rapidly evolving biotech landscape.